Storia: ZoeNCure Therapeutics Secures INR 20 Crore Seed Investment to Accelerate Next-Generation Antibody Drug Conjugate (ADC) Program

WARPTECHNEWS · LAB

Storia: ZoeNCure Therapeutics Secures INR 20 Crore Seed Investment to Accelerate Next-Generation Antibody Drug Conjugate (ADC) Program — Warptech Lab News

ZoeNCure Therapeutics Secures INR 20 Crore Seed Investment to Accelerate Next-Generation Antibody Drug Conjugate (ADC) Program

Timeline cronologica

ZoeNCure Therapeutics Secures INR 20 Crore Seed Investment to Accelerate Next-Generation Antibody Drug Conjugate (ADC) Program

ZoeNCure Therapeutics Secures License for Novel Antibody Platform from Styx Biotechnologies to Advance Next-Generation ADCs for Liver Cancer